The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technologies recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.<\/p>
<\/p>
The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE\u2019s updated methods guide will also be subject to a public consultation.<\/p>
<\/p>
NICE has established a working group, consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE\u2019s Senior Management Team, which in turn will report to the NICE Board. NICE approached patient groups with experience of NICE and its processes and methods. There are three patient group representatives on the working group with a wide range of experience, covering a range of topic areas, reflecting the programmes under review. Membership of the working group will be published in due course.<\/p>
<\/p>
NICE is now in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations with input from the working group and steering group. The scope of the review - a list of the aspects of NICE\u2019s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipates being in a position to confirm the revised methods guide by the end of 2020, following public consultation.<\/p>
<\/p>
<\/strong><\/p> <\/strong><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-06-20", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "263871"}
, {"_value" : "263872"}
, {"_value" : "263873"}
, {"_value" : "263874"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-06-20T13:18:08.087Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-06-12", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "National Institute for Health and Care Excellence"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, which topics have been identified for inclusion in the upcoming review of the appraisal methods used by NICE.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4382", "label" : {"_value" : "Biography information for Daniel Zeichner"}
}
, "tablingMemberConstituency" : {"_value" : "Cambridge"}
, "tablingMemberPrinted" : [{"_value" : "Daniel Zeichner"}
], "uin" : "263870"}
], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 1, "type" : "http://purl.org/linked-data/api/vocab#Page"}
}